IRLAB’s rights issue is now registered – conversion of BTA into shares
IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) issue of new shares of series A with preferential rights for existing shareholders, which was resolved by the Board of Directors on 24 June 2025 is now registered with the Swedish Companies Registration Office (Bolagsverket), and paid subscribed shares (“BTA”) will therefore be converted into shares.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.
IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) issue of new shares of series A with preferential rights for existing shareholders, which was resolved by the Board of Directors on 24 June 2025 is now registered with the Swedish Companies Registration Office (Bolagsverket), and paid subscribed shares (“BTA”) will therefore be converted into shares.
The last day of trading in BTA is August 18, 2025 and the record date with Euroclear Sweden AB is August 20, 2025. The newly issued shares are expected to be booked into the respective securities account/VP account on August 22, 2025.
Through the Rights Issue, IRLAB has received approximately SEK 115.7 million before issue costs.
Advisers
MAQS Advokatbyrå AB is legal advisor and Zonda Partners AB acts as financial advisor to the Company in connection with the Rights Issue.